ARTICLE | Company News
Promiliad, Spero Therapeutics, University of Connecticut deal
January 25, 2016 8:00 AM UTC
Promiliad granted Spero a worldwide, exclusive sublicense to develop and commercialize dihydrofolate reductase (DHFR) inhibitors that target Gram-positive and -negative bacteria, fungi and protists. ...